However, TIGIT was described to present more binding affinity for PVR than DNAM-1, which means that the expression of TIGIT on tumor-infiltrating lymphocytes is powerful enough to skew the immune response toward an immunosuppressed phenotype and therefore abrogates NK cell and CD8+ T cell cytotoxicity33. The gene discussed is CD226; the disease is neoplasm.